Related Experiment Videos
Pharmacogenetics of beta-blockers
1College of Pharmacy, Center for Pharmacogenetics, University of Florida, Gainesville, Florida 32610-0486, USA.
Pharmacotherapy
|June 5, 2007
Summary
Genetic variations influence how patients respond to beta-blockers, a key cardiovascular drug class. Understanding beta-blocker pharmacogenetics can personalize treatment for conditions like heart failure and hypertension.
Area of Science:
- Cardiovascular Pharmacology
- Pharmacogenetics
- Genetics
Background:
- Beta-blockers are essential cardiovascular drugs for treating heart failure, hypertension, angina, and post-myocardial infarction.
- Patient responses to beta-blocker therapy exhibit significant variability.
- Emerging research indicates that genetic polymorphisms play a role in this variable response.
Purpose of the Study:
- To review existing pharmacogenetic data for beta-blockers across various cardiovascular diseases.
- To explore the clinical implications of beta-blocker pharmacogenetics for patient treatment.
Main Methods:
- Systematic review of pharmacogenetic studies on beta-blockers.
- Analysis of genetic polymorphisms associated with beta-blocker efficacy and adverse events.
- Synthesis of data from diverse patient populations and disease states.
Main Results:
- Identified specific genetic polymorphisms linked to differential responses to beta-blockers.
- Demonstrated a correlation between genetic makeup and treatment outcomes in cardiovascular conditions.
- Highlighted the potential for genetic testing to guide beta-blocker selection.
Conclusions:
- Beta-blocker pharmacogenetics offers a promising avenue for personalized cardiovascular medicine.
- Incorporating genetic information into clinical practice may optimize beta-blocker therapy.
- Further research is warranted to fully elucidate the clinical utility of beta-blocker pharmacogenetics.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...